This company is no longer in business. Investors can get details about any potential exits or failures here.
NowRx
Technology-driven, on-demand pharmacy providing free, same-day delivery
Overview
Raised: $20,002,878
Total Commitments ($USD)
SeedInvest
08/13/2019
06/19/2020
$1,000
Equity - Preferred
RegA+
$3.45
$65,000,000
Rolling Commitments ($USD)
07/04/2020
$64,525
2015
Healthcare & Pharmaceuticals
HealthTech
Mountain View, California
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| NowRx | 05/19/2022 | SeedInvest | $275,000,000 | $30,006,323 | Equity - Preferred | Funded | RegA+ |
| NowRx | 10/04/2021 | SeedInvest | $275,000,000 | $3,635,310 | Equity - Preferred | Funded | Test the Waters / RegA+ |
| NowRx | 06/18/2020 | SeedInvest | $65,000,000 | $20,002,878 | Equity - Preferred | Funded | RegA+ |
| NowRx | 06/29/2018 | SeedInvest | $20,000,000 | - | Equity - Preferred | Funded | RegA+ |
| NowRx | 07/18/2017 | SeedInvest | $6,000,000 | - | Convertible Note | Funded | RegCF / RegD 506(c) |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Analyst Report 
Summary
NowRX has been selected as a “Top Deal” by KingsCrowd. Today, we are reiterating this Top Deal rating, reserved for the top 10% of all deals across the market. If you have questions regarding our deal diligence and selection methodology please reach out to hello@kingscrowd.com.
Since We Last Saw NowRx...
NowRx, a technology-driven, on-demand pharmacy, was rated a Top Deal by Kingscrowd in May of 2018. The team is now raising its Series B round as a Regulation A offer on SeedInvest with the ultimate goal of developing AI-powered robotic technology for free, same-day delivery of both prescription and over-the-counter (OTC) medications. In doing so, the team aims to eliminate the need for pharmacies altogether, heavily disrupting the $313B pharmaceutical market.
NowRx Financials Update
In March of 2018, NowRx closed its seed round at $1,345,000 on convertible note with a $10M valuation cap. Its series A closed in August of the same year at $6,796,700 in preferred equity with a $20M pre-money valuation. The current campaign offers preferred equity at a pre-money valuation of $65M.
NowRx revenues for 2018 were $4.7M, nearly a 90% increase from the previous year. Gross profit for 2018 was $634K, compared to $334K in 2017. With an increase in revenue from 2017 to 2018 also came an increase in total operating expenses, which stood at $1.3M and $3.5M, respectively.
As of July 2019, revenue stands at $7.2M. To date, NowRx has filled over 100k prescriptions. Though the valuation has gone up significantly, this significant increase in revenue and proven traction derisks the investment.
Why We (Continue To) Like It
- Ripe Market For Acquisition: When we last covered NowRx, it was rumored that PillPack was nearing acquisition. The company did in fact get acquired by Amazon in June of 2018 for $1B.
- Growth Plans: As of now, NowRx serves only the Bay area, making geographic expansion a natural next step in scaling. By 2023, NowRx plans to expand to 20 territories. This expansion will begin in the Los Angeles and Orange County areas and later move up and down the west coast with the ultimate goal of having 5-10 locations per metropolitan area. The team anticipates a 3x growth rate in its already established Bay Area base with the addition of these new locations due to the ramping up of customer marketing and sales efforts.
Since its last raise, NowRx has significantly sped up growth in the Bay Area where it was originally established. With each funding round, customer acquisition has increased. In addition, the team has opened two licensed micro-fulfilment centers in the Bay Area. A third facility in Orange County has also been leased. Retention rates are also high, with 86% of users claiming that it is “extremely likely” that they will use NowRx again. High satisfaction rate ground proof-of-concept before continuing geographic expansion.
- Data Aggregation: As with any machine-learning algorithm, the more data the better. NowRx has already acquired a substantial amount of customer data to better its systems. Efficiency and accuracy of these algorithms can only improve with more data. Not to mention, a large database could prove to be quite valuable in the event of a future acquisition, upping price point and overall value of the company.